ライフサイエンスコーパス: adrenergic receptor

1 TM6), similar to that observed for the beta2-adrenergic receptor.

2 d in Galphas upon binding of Gs to the beta2 adrenergic receptor.

3 tors, muscarinic acetylcholine receptor, and adrenergic receptor.

4 to decrease CXCL12 levels through the beta3-adrenergic receptor.

5 both the transferrin receptor and the beta2 adrenergic receptor.

6 gonist-GPCR complex of iodopindolol and beta-adrenergic receptor.

7 tion of presynaptic TRPV1 channels by alpha2 adrenergic receptors.

8 logical inhibition of muscarinic and/or beta-adrenergic receptors.

9 ion describing this drug class at the alpha1-adrenergic receptors.

10 , and is induced upon the activation of beta-adrenergic receptors.

11 rbutaline is mediated by activation of beta2-adrenergic receptors.

12 in iBAT was eliminated in mice lacking beta1-adrenergic receptors.

13 ne, histamine, melatonin, acetylcholine, and adrenergic receptors.

14 ed receptor desensitization, especially beta-adrenergic receptors.

15 bine, consistent with contribution of alpha2 adrenergic receptors.

16 ile POMC neurons are inhibited via alpha2A - adrenergic receptors.

17 and could be reversed by antagonism of beta3 adrenergic receptors.

18 teric modulation of the alpha1A- and alpha1B-adrenergic receptors.

19 that it was mediated by activation of alpha2 adrenergic receptors.

20 within a single subfamily, such as the nine adrenergic receptors.

21 Pharmacologic inhibition of beta2-adrenergic receptor 2 and protein kinase A, as well as s

22 otype had elevated serum titers of anti-beta-adrenergic receptor Abs, as well as increased protein ki

23 Here we show that beta-adrenergic receptors activate eight Galphas mutant prote

24 or cervical ganglion (SCG) neurons expressed adrenergic receptors (activated by epinephrine) and the

25 t, expended less energy in response to beta3-adrenergic receptor activation, and were more insulin re

26 voltage-dependent calcium channels upon beta-adrenergic receptor activation.

27 odopsin (visual receptor), opioid receptors, adrenergic receptors, adenosine receptors, dopamine rece

28 The alpha1D-adrenergic receptor (ADRA1D) is a key regulator of cardi

29 ing several Gi-GPCRs--including the alpha-2a adrenergic receptor, ADRA2A--increase the risk of type 2

30 The beta1-adrenergic-receptor (ADRB1) antagonist metoprolol reduce

31 Subsequently, we identified the beta2 adrenergic receptor (ADRB2) as a downstream target for P

32 us study, the Gly16Arg genotype of the beta2-adrenergic receptor (ADRB2) gene did not influence the d

33 reduced expression of the gene for the beta2-adrenergic receptor (ADRB2) in CD4(+) lymphocytes of sub

34 The effect of beta2-adrenergic receptor (ADRB2) polymorphisms on the treatme

35 or target of beta-agonist therapy, the beta2-adrenergic receptor (ADRB2).

36 Sustained beta3 adrenergic receptor (ADRB3) activation simultaneously up

37 eiging response: cold temperatures and beta3-adrenergic receptor (Adrb3) agonists.

38 Acute activation of beta3-adrenergic receptors (ADRB3) triggers lipolysis and up-r

39 aluated the associations of gene variants in adrenergic receptors (ADRs) with GAD, with the involveme

40 AR) in wound scarring, the ability of beta 2 adrenergic receptor agonist (beta2ARag) to alter HDF dif

41 or in combination with a long-acting beta2 -adrenergic receptor agonist (LABA) on GCM in the bronchi

42 rality were treated with the selective beta3 adrenergic receptor agonist CL 316, 243 and underwent me

43 Treatment with the beta3-adrenergic receptor agonist CL316,243 increased Cx43 exp

44 In humans, the alpha2-adrenergic receptor agonist clonidine increases decisive

45 nantioselective total synthesis of the beta3-adrenergic receptor agonist Solabegron.

46 Salmeterol is a long-acting beta2-adrenergic receptor agonist used to treat chronic obstru

47 hat orally administered DL-isoproterenol, an adrenergic receptor agonist whose skeleton includes 1,2-

48 Significance statement: Clonidine, an alpha2-adrenergic receptor agonist, which decreases the level o

49 hma exacerbation is the short-acting beta(2)-adrenergic receptor agonist; however, there is variation

50 chanism of Rett syndrome and introduce beta2-adrenergic receptor agonists as potential therapeutic ag

51 ved with adrenergic function were genotyped; adrenergic receptors alpha(1A) (ADRA1A), alpha(2A) (ADRA

52 a G protein-coupled receptor, the alpha(2A) adrenergic receptor (alpha(2A)AR).

53 e recruitment of GRK2 to activated alpha(2A)-adrenergic receptors (alpha(2A)ARs) in living cells.

54 art failure, common genetic variants of beta-adrenergic receptors, alpha-adrenergic receptors, and en

55 AgNO3 inhibited ligand binding to adrenergic receptors alpha1 and alpha2 and cannabinoid r

56 vasopressin receptor (V1A-R) but not alpha1 adrenergic receptor (alpha1-AR), suggesting that GPCR pr

57 In contrast, activation of alpha1B-adrenergic receptors (alpha1B-ARs) induced transient inh

58 lutionary precursor to the vertebrate alpha2-adrenergic receptors (alpha2-ARs) based upon sequence si

59 gulation of cell surface transport of alpha2-adrenergic receptors (alpha2-ARs) by GGA3 (Golgi-localiz

60 rect interaction between APP and the alpha2A-adrenergic receptor (alpha2AAR) that occurs at the intra

61 ered to the carboxyl terminus of the alpha2A adrenergic receptor (alpha2AAR-Galphai2YFP).

62 A2) in the cell surface transport of alpha2B-adrenergic receptor (alpha2B-AR), a prototypic GPCR, and

63 The human alpha2C-adrenergic receptor (alpha2C-AR) is localized intracellu

64 models incorporating the structures of beta2-adrenergic receptor and 5-HT2B receptor.

65 rine, a catecholamine that binds to the beta-adrenergic receptor and activates the cAMP-PKA-dependent

66 G-protein binding site of an activated beta2 adrenergic receptor and form salt-bridge interactions th

67 beta-Adrenergic receptor and inotropic response were decrease

68 2, whereas two Rhodopsin-family GPCRs, beta2-adrenergic receptor and mCannR2, exhibit colocalization

69 tures: the adenosine A2A receptor, the beta2-adrenergic receptor and rhodopsin.

70 It is known that beta-adrenergic receptors and NA can boost LTP maintenance by

71 n dissociation from the alpha1A- and alpha1B-adrenergic receptors and noncompetitively inhibit recept

72 ediastinum ratio, reflecting the function of adrenergic receptors and sympathetic activity, were posi

73 erties on I1 imidazoline receptors vs alpha2-adrenergic receptors and their blood pressure effects af

74 mpal LTP, decreased neuronal levels of beta2-adrenergic receptors, and activated microglia in wt mice

75 tested for the beta2-, alpha1-, and alpha2- adrenergic receptors, and adenosine type 1 receptor (A1R

76 variants of beta-adrenergic receptors, alpha-adrenergic receptors, and endothelin receptors (among ot

77 Adrenergic receptors, and perhaps other GPCRs, represent

78 beta-adrenergic receptor antagonism after experimental stroke

79 1 (CRF1) antagonist (antalarmin), and alpha2-adrenergic receptor antagonist (yohimbine; used as a pha

80 Neither norepinephrine nor adrenergic receptor antagonist infusion into the auditor

81 4 h or by intravenous infusion of the alpha-adrenergic receptor antagonist phentolamine for only 30

82 We find that administration of the beta-adrenergic receptor antagonist propranolol before memory

83 The beta-adrenergic receptor antagonist propranolol, administered

84 ies is also enhanced by administering a beta-adrenergic receptor antagonist to mice housed at 22 degr

85 Cotreatment with a beta2-adrenergic receptor antagonist, butoxamine, suggests tha

86 ression, but pre-exposure to timolol, a beta-adrenergic receptor antagonist, delayed this effect.

87 Orthosteric beta-adrenergic receptor antagonists, known as beta-blockers,

88 Epinephrine or the beta3-adrenergic receptor (AR) agonist CL 316,243 (CL) stimula

89 handgrip-exercise ischaemia (PEI) and beta1 -adrenergic receptor (AR) blockade.

90 inal cells in high glucose and of the alpha1-adrenergic receptor (AR) on vascular lesions of the reti

91 review, we discuss the contribution of each adrenergic receptor (AR) subtype (alpha1, alpha2, and be

92 and determine the roles of alpha1- and beta-adrenergic receptors (AR) in the loss-of-interest in foo

93 alpha2-adrenergic receptors (AR) within the bed nucleus of the

94 Adrenergic receptors are expressed on the surface of inf

95 The alpha1-adrenergic receptors are targets for a number of cardiov

96 Adrenergic receptors are the primary target for GRK2 act

97 iprocal down-regulation occurs between beta1-adrenergic receptors (ARs) and the cardioprotective sphi

98 Agonist-triggered downregulation of beta-adrenergic receptors (ARs) constitutes vital negative fe

99 od pressure through interactions with alpha1-adrenergic receptors (ARs) in vascular smooth muscle.

100 cular myocyte expresses all 5 of the cardiac adrenergic receptors (ARs), beta1, beta2, beta3, alpha1A

101 Noradrenaline acts through adrenergic receptors (ARs), of which beta2-adrenergic re

102 noradrenergic innervation and expresses beta adrenergic receptors (ARs).

103 Using the beta2-adrenergic receptor as a model, we present a proof of co

104 knockdown reduces extrasynaptic insertion of adrenergic receptors as well as functional expression of

105 Retromer-associated endosomes contain beta-adrenergic receptors as well as ionotropic glutamate rec

106 Real-time cAMP analysis in beta1- and beta2-adrenergic receptor-associated membrane microdomains usi

107 teracts with the BiOctR, DmOctR, and alpha2C-adrenergic receptor at an allosteric site.

108 The prototypical beta-2 adrenergic receptor (B2AR) activates Galpha stimulatory

109 luteinizing hormone receptor (LHR) and beta2-adrenergic receptor (B2AR), two GPCRs sorted to the regu

110 Bioinformatics analysis revealed the adrenergic receptor beta-1 (Adrb1) as a potential target

111 predicting activation pathways of the beta 2-adrenergic receptor (beta 2-AR), folding of the FiP35 WW

112 y, we and others have demonstrated that beta-adrenergic receptor (beta-AR) activation is necessary fo

113 is markedly induced in the heart after beta-adrenergic receptor (beta-AR) activation.

114 beta-Adrenergic receptor (beta-AR) blockers administered to c

115 We used beta-adrenergic receptor (beta-AR) signaling as a prototype t

116 tumor microenvironment is regulated by beta2-adrenergic receptor (beta-AR) signaling in host immune c

117 While beta-adrenergic receptor (beta-AR) stimulation ensures adequa

118 Intracellular Ca(2+) ([Ca(2+) ]i ) and beta-adrenergic receptor (beta-AR) stimulation modulate IKs a

119 d in cardiac dysfunction during chronic beta-adrenergic receptor (beta-AR) stimulation.

120 s myocardial calcium transients through beta-adrenergic receptor (beta-AR)-mediated phosphorylation o

121 It causes pathologic desensitization of beta-adrenergic receptors (beta-AR), facilitated predominantl

122 stimulates contractility by activating beta-adrenergic receptors (beta-AR).

123 sympathetic nerve fibers, expression of beta-adrenergic receptors (beta-ARs) and remodeling parameter

124 associated with enhanced stimulation of beta-adrenergic receptors (beta-ARs).

125 The beta1-adrenergic receptor (beta1-AR) is a target for treatment

126 uces activation of the MAPK pathway by beta1-adrenergic receptor (beta1AR) agonists.

127 Based on bioinformatic analysis, beta1-adrenergic receptor (beta1AR) and other components of th

128 The beta1-adrenergic receptor (beta1AR) is a G protein-coupled rec

129 The beta1 adrenergic receptor (beta1AR) is recognized as a classic

130 re, we hypothesized that activation of beta1-adrenergic receptors (beta1ARs) localized to ghrelin cel

131 beta1-adrenergic receptors (beta1ARs) mediate catecholamine ac

132 Recent research has revealed that beta2 -adrenergic receptor (beta2 -AR) agonists lose bronchodil

133 t elevation of phosphorylation of the beta2 -adrenergic receptor (beta2 AR) at both the protein kinas

134 timulated by two Gs-coupled receptors, beta2-adrenergic receptor (beta2-AR) and D1 dopamine receptor

135 notypic pharmacology of ligands at the beta2-adrenergic receptor (beta2-AR) stably expressed in HEK-2

136 activation and internalization of the beta2-adrenergic receptor (beta2-AR), a prototypic G-protein c

137 to selective interactions between the beta2-adrenergic receptor (beta2-AR)-Galphas and V1A receptor

138 plasma membrane upon coexpression with beta2-adrenergic receptors (beta2-ARs) through an interaction

139 show in atomistic detail how the human beta2-adrenergic receptor (beta2AR) - a prototypical G protein

140 In this article, we demonstrate that beta2-adrenergic receptor (beta2AR) activation in LPS-stimulat

141 The beta-2 adrenergic receptor (beta2AR) agonist formoterol induces

142 Salmeterol is a long-acting beta2-adrenergic receptor (beta2AR) agonist that is widely use

143 pertrophy stimulated by clenbuterol, a beta2-adrenergic receptor (beta2AR) agonist, was significantly

144 beta2-Adrenergic receptor (beta2AR) agonists are critical trea

145 PCL interacts with beta2-adrenergic receptor (beta2AR) and co-localizes with beta

146 el G-protein-coupled receptors (GPCRs) beta2-adrenergic receptor (beta2AR) and Mu-opioid receptor (MO

147 n high-resolution x-ray structures of the ?2 adrenergic receptor (beta2AR) and other GPCRs, the bindi

148 ed for agonist-bound structures of the beta2-adrenergic receptor (beta2AR) and the M2 muscarinic rece

149 ipitated with overexpressed TPbeta and beta2-adrenergic receptor (beta2AR) in HEK 293 cells, but also

150 To investigate the role of the beta 2 adrenergic receptor (beta2AR) in wound scarring, the abi

151 The beta2-adrenergic receptor (beta2AR) is a prototypical G protei

152 -15) is an allosteric modulator of the beta2 adrenergic receptor (beta2AR) that was recently isolated

153 aging, we examine TM6 movements in the beta2 adrenergic receptor (beta2AR) upon exposure to orthoster

154 amics of the cytoplasmic domain of the beta2-adrenergic receptor (beta2AR) using (19)F-fluorine NMR a

155 onsider oligomerization of the class A beta2 adrenergic receptor (beta2AR), and reevaluate BRET titra

156 ine 2B receptor (A2BR), but not of the beta2 adrenergic receptor (beta2AR), leading to an enhanced, a

157 e membrane-proximal amino acids of the beta2 adrenergic receptor (beta2AR), the sphingosine 1-phospha

158 ic Cy3 fluorescence probe in the human beta2-adrenergic receptor (beta2AR), we observed that individu

159 n by comparing human Wntless (Wls) and beta2 adrenergic receptor (beta2AR), which require retromer ph

160 3 in regulating the trafficking of the beta2-adrenergic receptor (beta2AR).

161 g to analyze GRK5 interaction with the beta2-adrenergic receptor (beta2AR).

162 tabilize an active conformation of the beta2-adrenergic receptor (beta2AR).

163 ree different conformational states of beta2-adrenergic receptor (beta2AR): 1), the inverse-agonist-b

164 e find, however, that co-expression of beta2-adrenergic receptors (beta2AR) in HEK-293T routes TAS2R1

165 report here that a population of human beta2-adrenergic receptors (beta2AR), a canonical G protein-co

166 ogy, we removed the gene encoding the beta-2 adrenergic receptors (beta2ARs) from a mouse model overe

167 viously demonstrated the importance of beta2-adrenergic receptors (beta2ARs) in the regulation of imm

168 ing and recycling of agonist-activated beta2 adrenergic receptors (beta2ARs).

169 by the sympathetic nervous system via beta3-adrenergic receptors (beta3-AR).

170 A) are the most widely studied steps in beta-adrenergic receptor (betaAR) signaling in the heart; how

171 population of Galphai and its coupled beta2-adrenergic receptor (betaAR), are localized to caveola d

172 by hydrolysis of triglycerides through beta-adrenergic receptor (betaARs) and protein kinase A (PKA)

173 beta-adrenergic receptors (betaARs) are critical regulators o

174 Beta adrenergic receptors (betaARs) are G-protein-coupled rec

175 h adrenergic receptors (ARs), of which beta2-adrenergic receptors (betaARs) are of particular importa

176 In heart failure, the beta-adrenergic receptors (betaARs) become desensitized and u

177 Activation of beta-adrenergic receptors (betaARs) enhances both the inducti

178 Stimulation of beta-adrenergic receptors (betaARs) provides the most efficie

179 phrine, a neuromodulator that activates beta-adrenergic receptors (betaARs), facilitates learning and

180 norepinephrine, through its actions on beta-adrenergic receptors (betaARs), modulates aversive memor

181 regulate immune system function through beta-adrenergic receptors (betaARs); however, their role in r

182 In contrast, during beta1 -adrenergic receptor blockade, LV apical rotation, twist

183 , ganglionic-blocker administration or beta2-adrenergic receptor blockade.

184 ing post-exercise ischaemia (PEI) and beta1 -adrenergic receptor blockade.

185 beta2-Adrenergic receptor blocker treatment reduced arrhythmia

186 beta-Adrenergic receptor blockers (beta-blockers) are commonl

187 patients with heart failure, for which beta-adrenergic receptor blockers are a mainstay therapy.

188 raction, 0.24+/-0.09) were randomized to the adrenergic-receptor blockers metoprolol (beta1-selective

189 ontrols trafficking of the interacting beta1-adrenergic receptor both in the anterograde, biosyntheti

190 The structures of beta2-adrenergic receptor bound with a variety of ligands prov

191 The stimulation of beta-adrenergic receptors by isoproterenol (ISO) resulted in

192 Inhibition of the beta-adrenergic receptor/cAMP/PKA axis protected against the

193 , which was increased by 5-HT(1A) and alpha2-adrenergic receptor co-activation in an activator of G p

194 Upon agonist stimulation, alpha1B-adrenergic receptors couple to Gq proteins, calcium sign

195 e T-type Ca(2+) current is initiated by beta-adrenergic receptors, cyclic AMP and cyclic AMP-dependen

196 This change was initiated by beta-adrenergic receptors, cyclic AMP and protein kinase A as

197 In further mechanistic studies using beta2-adrenergic receptor-deficient (beta2-AR(-/-)) mice, we f

198 the delta-opioid receptor, but not the beta2-adrenergic receptor, defining a role for CLCs in the upt

199 Further, we demonstrate that beta2-adrenergic receptor-dependent activation of proinflammat

200 brain dopaminergic neurons through an alpha1 adrenergic receptor-dependent mechanism within the ventr

201 d by acute treadmill exercise through a beta-adrenergic receptor-dependent mechanism.

202 e increases SKM D2 expression through a beta-adrenergic receptor-dependent mechanism.

203 This suggests that signaling by beta-adrenergic receptors depends on temporal pattern of stim

204 nalysis suggests that activation of the beta-adrenergic receptor either via canonical (Gs-coupled) or

205 amyloid precursor protein modulates alpha2A-adrenergic receptor endocytosis and signaling through di

206 antly, phosphorylation of the inactive beta2-adrenergic receptor enhanced its interactions with arres

207 s is transduced by the beta2, but not beta3, adrenergic receptor expressed on stromal cells of leukem

208 y reflecting down-regulation of cardiac beta-adrenergic receptor function in chronic hypoxia.

209 rescent proteins and four GPCRs: the alpha2A-adrenergic receptor, GABAB, cannabinoid receptor type 1

210 cently labeled Galphai1 subunits and alpha2A-adrenergic receptor, GABAB, or dopamine receptor type 2

211 ), and this is pivotal to activate the beta1-adrenergic receptor gene (Adrb1) and downstream targets

212 The beta2-adrenergic receptor gene (ADRB2) contains a common, non-

213 sal of gene expression controlled by a beta1-adrenergic receptor gene network.

214 an architecture similar to that of the beta2-adrenergic receptor-GS complex, including a flexible alp

215 and active experimental structures of beta2 adrenergic receptor (hbeta2AR) and M2 muscarinic acetylc

216 In mice with genetic deficiency of the beta3 adrenergic receptor, hematopoietic stem cells did not en

217 rget effects on other endogenously expressed adrenergic receptors, highlighting the importance of tho

218 nsistent with the crystal structure of beta2 adrenergic receptor in complex with Gs Conformational ch

219 hearts, because of desensitization of beta1-adrenergic receptor in heart failure.

220 onto the extracellular domain of the Beta-2 adrenergic receptor in HEK293T cells, followed by incuba

221 lations to explore dimerization of the beta2-adrenergic receptor in lipid bilayers containing cholest

222 expression of alpha2A-, alpha2B- and alpha2C-adrenergic receptors in both populations.

223 eatly reduced, suggesting that activation of adrenergic receptors in DRG neurons is preferentially li

224 because of, for example, activation of beta1-adrenergic receptors in myocardium.

225 activation of excitatory alpha1A - and beta- adrenergic receptors in NPY/AgRP neurons, while POMC neu

226 Sympathetic stimulation of beta-adrenergic receptors in response to cold induces prolife

227 anism underlying the critical role of alpha1 adrenergic receptors in the regulation of dopamine neuro

228 model G protein-coupled receptor, the beta2-adrenergic receptor, including experiments that characte

229 Carabin also conferred protection against adrenergic receptor-induced hypertrophy in isolated card

230 sin II receptors blockade nor alpha and beta adrenergic receptors inhibition blunted leptin-induced a

231 een established that stimulation of the beta-adrenergic receptor inhibits insulin-stimulated glucose

232 beta-Adrenergic receptor kinase 1 (betaARK 1 or GRK2) mediate

233 ERK1/2 activation through activation of beta-adrenergic receptor kinase 1.

234 ein-coupled receptor kinase 3 (GRK3; or beta-adrenergic receptor kinase 2) was not only necessary for

235 dothelial Adrb2, the gene encoding the beta2-adrenergic receptor, leads to inhibition of angiogenesis

236 that downregulation of Rnd3 attenuated beta2-adrenergic receptor lysosomal targeting and ubiquitinati

237 cardiac autonomic function and damage to the adrenergic receptors may contribute to the development o

238 Additionally, we report that beta-adrenergic receptors mediate the anxiety-like phenotype

239 ered to be the predominant regulator of beta-adrenergic receptor-mediated enhancement of cardiac cont

240 Higher levels of GRK2 can impair beta-adrenergic receptor-mediated inotropic reserve and its i

241 l of arousal by selectively targeting alpha2 adrenergic receptors on LC neurons, resulting in reduced

242 ularis and norepinephrine signaling to beta2 adrenergic receptors on MMs.

243 Here we show that a chimeric rhodopsin/beta2 adrenergic receptor (opto-beta2AR) is similar in dynamic

244 receptor composed of rhodopsin and the beta2-adrenergic receptor (Opto-beta2AR) with in vivo optogene

245 ycling by activation of alpha1- and/or beta3-adrenergic receptors or the SERCA2b-RyR2 pathway stimula

246 ssociated with significant changes in beta2 -adrenergic receptor phosphorylation at protein kinase A

247 Upon activation of beta-adrenergic receptors, phosphorylation of CaV1.2 channels

248 h in turn resulted in the elevation of beta2-adrenergic receptor protein levels leading to the hypera

249 raffic were investigated by studying alpha1B-adrenergic receptor-Rab protein interactions, using Fors

250 n several important cellular processes (beta-adrenergic receptor recycling, centrosome amplification,

251 c effects via activation of beta2 and alpha2 adrenergic receptors, respectively.

252 rown adipocytes, displayed an impaired beta3-adrenergic receptor response that was characterized by a

253 gh-resolution crystal structure of the beta2-adrenergic receptor revealed the presence of possible ch

254 gnaling profiles of 28 variants of the beta2-adrenergic receptor reveals three clearly distinct pheno

255 able to normalize the distribution of beta2 adrenergic receptor signal by preventing PKA signal acce

256 further demonstrate that the endosomal beta2-adrenergic receptor signal confers uniformity on the dow

257 mpacts of high-fat diet (HFD) on the insulin-adrenergic receptor signal network in hearts.

258 e recently uncovered an insulin receptor and adrenergic receptor signal network in the heart.

259 myofilaments is because of an enhanced beta2 adrenergic receptor signal selectively directed to the m

260 ction of caveolin-3 is able to confine beta2 adrenergic receptor signaling and restore myocyte contra

261 hese data reveal how baseline levels of beta-adrenergic receptor signaling can influence murine GVHD

262 rabbit myocytes, selectively enhanced beta2 adrenergic receptor signaling toward the myofilaments co

263 ostate cancer, we show that endothelial beta-adrenergic receptor signaling via adrenergic nerve-deriv

264 duction and excessive signaling through beta-adrenergic receptor signaling, which is increased when m

265 helin-1, renin-angiotensin, and cardiac beta-adrenergic receptor signaling, which were not inhibited

266 d in HF patients, causing dysfunctional beta-adrenergic receptor signaling.

267 brown adipocytes through modulation of beta-adrenergic receptor signaling.

268 rmone-responsive, and are regulated by beta1-adrenergic receptor signaling.

269 function and is mediated, in part, by beta1-adrenergic receptor signaling.

270 fat diet (HFD) feeding on the cardiac beta2 -adrenergic receptor signalling and the impacts on cardia

271 r the same receptor molecule (e.g., the beta-adrenergic receptor), some agonists have a propensity to

272 s of cell shortening revealed augmented beta-adrenergic receptor-stimulated cardiomyocyte contractili

273 pocytes, insulin was unable to suppress beta-adrenergic receptor-stimulated glycerol release.

274 potential duration, supersensitivity to beta-adrenergic receptor stimulation and Ca(2+) mishandling f

275 Here we show that BAT activation by beta3-adrenergic receptor stimulation protects from atheroscle

276 Local beta-adrenergic receptor stimulation with noradrenaline (nore

277 out which signals activate BA, besides beta3-adrenergic receptor stimulation, is limited.

278 018 is phosphorylated and activated by beta1-adrenergic receptor stimulation-induced EGF receptor (EG

279 retion of alpha-amylase secretion after beta-adrenergic receptor stimulation.

280 Here we show that mutation in the alpha2 -adrenergic receptor subtype B (alpha2B -AR) is associate

281 -coupled receptor (GPCR) and the predominant adrenergic receptor subtype in the heart, where it media

282 dose SNRIs, by acting on 5-HT(1A) and alpha2-adrenergic receptors, synergistically reduced AMPA recep

283 imera containing the type I PDZ of the beta2-adrenergic receptor that does not bind to SAP97 failed t

284 When alpha1B-adrenergic receptors that had been mutated at protein ki

285 and active in costimulating, with the alpha1-adrenergic receptor, the firing of DR 5-HT neurons, whil

286 In the case of the beta2 adrenergic receptor, these ligands are generally small-m

287 ands and investigated their impacts on beta2-adrenergic receptor through a total of 12 x 100 ns molec

288 through signaling pathways identical to beta-adrenergic receptors, thus providing support that inhibi

289 NE enhances thermogenesis through beta3-adrenergic receptors to activate brown adipose tissue an

290 from impaired signal transduction from beta-adrenergic receptors to adenylate cyclase.

291 thways and discovered that NA activates beta-adrenergic receptors to boost LTP maintenance in area CA

292 ular populations that express different beta-adrenergic receptors to induce beige adipogenesis.

293 gest that protein kinase C modulates alpha1B-adrenergic receptor transfer to late endosomes and that

294 echanism that attenuates Rnd3-mediated beta2-adrenergic receptor ubiquitination, which leads to the a

295 map the oligomerization energy of the beta2-adrenergic receptor using approximately 10(9)-fold less

296 for a set of small molecules with the beta2 adrenergic receptor, we demonstrate that deconvolution o

297 ng (13)C methyl methionine NMR for the beta1-adrenergic receptor, we identify ligand efficacy-depende

298 We observed that the content of beta2-adrenergic receptors, which are mainly expressed in skel

299 s also shown to be a modulator of the alpha1-adrenergic receptors, which suggests a general lack of s

300 ction that a complete antagonist of the beta-adrenergic receptor will likely block long-lasting LTP i

301 Stimulation of Galphas-coupled beta-adrenergic receptors with isoproterenol induced PKA-depe